We are extremely happy to announce that our Bupropion 150mg Modified-release (MR) tablets has passed the pivotal bioequivalence studies and the dossier will be ready for filing in March 2021. Having both strengths (150 & 300mg) finally available in Intas B2B portfolio, our clients will have access to the entire market.
Bupropion MR 150mg tablet is a complex development, but our great R&D Team has made it possible!
Join us to discover our product portfolio and latest updates:
www.intasportfolio.com
